Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CAMBRIDGE, Mass., Feb. 11, 2016 -- Proteostasis Therapeutics, Inc. today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Proteostasis Therapeutics, Inc. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock from the company at the public offering price. The company’s shares are expected to begin trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol “PTI.” The offering is expected to close on February 17, 2016 subject to customary closing conditions.
Leerink Partners and RBC Capital Markets are acting as joint book-running managers. Baird and H.C. Wainwright & Co. are acting as co-managers.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on February 10, 2016. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Leerink Partners LLC, c/o Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808-7525, ext. 6142; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact: Dan Budwick, Pure Communications [email protected] 973-271-6085 Investor Contact: Luke Heagle, Pure Communications [email protected] 910-726-1372
